It is exciting that four compounds – used in other diseases such as prostate cancer – targeted HDAC4 activity, reversed the impaired expression of the HDAC4-controlled genes and subsequently ameliorated pertubations in autophagy and lysosomal pathways. This evidence concerns the gene HDAC4 and prostate cancer.